nach oben

Current Hepatology Reports

Erschienen in:

31.07.2019 | Hepatitis B (JK Lim, Section Editor)

Epidemiology, Diagnosis, and Management of Bone Disease in Patients with Chronic HBV Infection

verfasst von: Mike T. Wei, Mindie H. Nguyen, Ramsey Cheung

Erschienen in: Current Hepatology Reports | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Chronic hepatitis B (CHB) and treatment may be associated with increased risk of osteopenia/osteoporosis. Here, we review the prevalence of osteopenia/osteoporosis among patients with CHB and the effect of antiviral therapy on bone density. We also highlight screening and management strategies for bone disease among patients with CHB.

Recent Findings

While there are concerns with first-line antiviral therapy such as tenofovir disoproxil fumarate in the development of osteopenia/osteoporosis, the available data remain rather unclear. However, with the development of tenofovir alafenamide, these concerns may be mitigated. At present, EASL recommends dual-energy X-ray absorption (DEXA) scans for patients with osteoporotic risk factors, with a repeat DEXA scan based upon baseline findings.

Summary

Patients with CHB have higher incidence and prevalence of osteopenia/osteoporosis compared with patients without CHB. Further studies are needed to understand the impact of antiviral therapy on bone therapy, and more CHB specific recommendations are needed for bone health management.

MacLachlan JH, Locarnini S, Cowie BC. Estimating the global prevalence of hepatitis B. Lancet. 2015;386(10003):1515–7. https://doi.org/10.1016/S0140-6736(15)61116-3.CrossRefPubMed

World Health Organization. Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en/. 2017.

Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55. https://doi.org/10.1016/S0140-6736(15)61412-X.CrossRefPubMed

Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319(17):1802–13. https://doi.org/10.1001/jama.2018.3795.CrossRefPubMed

• National Institutes of Health. Osteoporosis overview. https://www.bones.nih.gov/health-info/bone/osteoporosis/overview. an on-line overview on the topic.

Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract. 2016;22(Suppl 4):1–42. https://doi.org/10.4158/EP161435.GL.CrossRefPubMed

World Health Organization. WHO scientific group on the assessment of osteoporosis at primary health care level. 2007.

Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81. https://doi.org/10.1007/s00198-014-2794-2.CrossRefPubMedPubMedCentral

Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–6. https://doi.org/10.1002/jbmr.2269.CrossRefPubMed

10.

Guarino M, Loperto I, Camera S, Cossiga V, Di Somma C, Colao A, et al. Osteoporosis across chronic liver disease. Osteoporos Int. 2016;27(6):1967–77. https://doi.org/10.1007/s00198-016-3512-z.CrossRefPubMed

11.

Wariaghli G, Mounach A, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, et al. Osteoporosis in chronic liver disease: a case-control study. Rheumatol Int. 2010;30(7):893–9. https://doi.org/10.1007/s00296-009-1071-8.CrossRefPubMed

12.

Leslie WD, Bernstein CN, Leboff MS, Commitee AGACP. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology. 2003;125(3):941–66.CrossRefPubMed

13.

Baeg MK, Yoon SK, Ko SH, Han KD, Choi HJ, Bae SH, et al. Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys. Hepatol Int. 2016;10(3):470–7. https://doi.org/10.1007/s12072-015-9672-7.CrossRefPubMed

14.

Collier J. Bone disorders in chronic liver disease. Hepatology. 2007;46(4):1271–8. https://doi.org/10.1002/hep.21852.CrossRefPubMed

15.

Chen CH, Lin CL, Kao CH. Association between chronic hepatitis B virus infection and risk of osteoporosis: a nationwide population-based study. Medicine (Baltimore). 2015;94(50):e2276. https://doi.org/10.1097/MD.0000000000002276.CrossRef

16.

Gallego-Rojo FJ, Gonzalez-Calvin JL, Muñoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. 1998;28(3):695–9. https://doi.org/10.1002/hep.510280315.CrossRefPubMed

17.

Tien C, Xu JJ, Chan LS, Chang M, Lim C, Lee S, et al. Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. Dig Dis Sci. 2015;60(2):566–72. https://doi.org/10.1007/s10620-014-3363-4.CrossRefPubMed

18.

• Nguyen MH, Lim JK, Ozbay AB, Fraysse J, Liou I, Meyer N, et al. Advancing age and comorbidity in a United States insured population-based cohort of patients with chronic hepatitis B. Hepatology. 2018. https://doi.org/10.1002/hep.30246 large population-based study from the U.S.

19.

Liu A, Le A, Zhang J, Wong C, Henry L, Nguyen MH. Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015. Clin Transl Gastroenterol. 2018;9(3):141. https://doi.org/10.1038/s41424-018-0007-6.CrossRefPubMedPubMedCentral

20.

Wei MT, Le AK, Chang MS, Hsu H, Nguyen P, Zhang JQ, et al. Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. J Med Virol. 2019;91:1288–94. https://doi.org/10.1002/jmv.25433.CrossRefPubMed

21.

• European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. https://doi.org/10.1016/j.jhep.2017.03.021. Practice guidelines on management of chronic hepatitis B.

22.

• Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018. https://doi.org/10.1002/hep.29800 Practice guidelines on management of chronic hepatitis B.

23.

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. https://doi.org/10.1007/s12072-015-9675-4.CrossRefPubMed

24.

Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis. 2015;211(3):374–82. https://doi.org/10.1093/infdis/jiu471.CrossRefPubMed

25.

Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201. https://doi.org/10.1001/jama.292.2.191.CrossRefPubMed

26.

Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49(10):1591–601. https://doi.org/10.1086/644769.CrossRefPubMed

27.

Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963–72. https://doi.org/10.1086/656417.CrossRefPubMed

28.

Hsu YC, Wei MT, Nguyen MH. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol. 2017;11(11):999–1008. https://doi.org/10.1080/17474124.2017.1386554.CrossRefPubMed

29.

Fung J, Seto WK, Lai CL, Yuen MF. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014;29(3):428–34. https://doi.org/10.1111/jgh.12499.CrossRefPubMed

30.

Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457–64. https://doi.org/10.1007/s10620-014-3486-7.CrossRefPubMed

31.

Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146(4):980–8. https://doi.org/10.1053/j.gastro.2013.12.028.CrossRefPubMed

32.

Maggi P, Montinaro V, Leone A, Fasano M, Volpe A, Bellacosa C, et al. Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. J Antimicrob Chemother. 2015;70(4):1150–4. https://doi.org/10.1093/jac/dku502.CrossRefPubMed

33.

Wong GL, Tse YK, Wong VW, Yip TC, Tsoi KK, Chan HL. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53,500 subjects. Hepatology. 2015;62(3):684–93. https://doi.org/10.1002/hep.27894.CrossRefPubMed

34.

Bunchorntavakul C, Taweewattanakitbavorn V, Atsawarungruangkit A. Bone mineral density and renal function in chronic hepatitis B patients receiving nucleotide versus nucleoside analogs: a pilot prospective study. J Med Assoc Thail. 2016;99(Suppl 2):S1–8.

35.

Saeedi R, Mojebi-Mogharar A, Sandhu SK, Dubland JA, Ford JA, Yousefi M, et al. Lamivudine, entecavir, or tenofovir treatment of hepatitis B infection: effects on calcium, phosphate, FGF23 and indicators of bone metabolism. Ann Hepatol. 2017;16(2):207–14. https://doi.org/10.5604/16652681.1231577.CrossRefPubMed

36.

Tonon M, Piano S, Romano A, Fasolato S, Stanco M, Pilutti C, et al. Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir. Eur J Gastroenterol Hepatol. 2018:1. https://doi.org/10.1097/MEG.0000000000001051.

37.

Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449–55. https://doi.org/10.1097/QAI.0b013e3182965d45.CrossRefPubMed

38.

Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015;62(3):533–40. https://doi.org/10.1016/j.jhep.2014.10.035.CrossRefPubMed

39.

Wei MT, Le AK, Chang MS, Hsu Y-C, Nguyen P, Zhang JQ et al. Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. 2018.

40.

•• Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196–206. https://doi.org/10.1016/S2468-1253(16)30107-8 Tenofovir alafenamide clinical trial. CrossRefPubMed

41.

•• Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185–95. https://doi.org/10.1016/S2468-1253(16)30024-3 Tenofovir alafenamide clinical trial. CrossRefPubMed

42.

Seto WK, Asahina Y, Brown TT, Peng CY, Stanciu C, Abdurakhmanov D, et al. Improved bone safety of tenofovir alafenamide compared to tenofovir disoproxil fumarate over 2 years in patients with chronic HBV infection. Clin Gastroenterol Hepatol. 2018. https://doi.org/10.1016/j.cgh.2018.06.023.

43.

Li J, Chang MS, Tran TT, Nguyen MH. Management of chronic hepatitis B in pregnancy. J Clin Gastroenterol. 2017;51(9):789–95. https://doi.org/10.1097/MCG.0000000000000908.CrossRefPubMed

44.

Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002;50(Suppl 1):i1–9.CrossRefPubMedPubMedCentral

45.

•• European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172–93. https://doi.org/10.1016/j.jhep.2018.06.024. EASL guidelines on bone disease and management in patient with chronic liver disease.

46.

Chaney A, Heckman MG, Diehl NN, Meek S, Keaveny AP. Effectiveness and outcomes of current practice in treating vitamin D deficiency in patients listed for liver transplantation. Endocr Pract. 2015;21(7):761–9. https://doi.org/10.4158/EP14416.OR.CrossRefPubMed

47.

Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med. 2017;167(3):ITC17–32. https://doi.org/10.7326/AITC201708010.CrossRefPubMed

48.

• Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for osteoporosis to prevent fractures: US preventive services task force recommendation statement. JAMA. 2018;319(24):2521–31. https://doi.org/10.1001/jama.2018.7498 General recommendation on screening for osteoporosis. CrossRefPubMed

49.

Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology. 2005;42(4):762–71. https://doi.org/10.1002/hep.20866.CrossRefPubMed

50.

Guañabens N, Parés A, Ros I, Alvarez L, Pons F, Caballería L, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98(10):2268–74. https://doi.org/10.1111/j.1572-0241.2003.07639.x.CrossRefPubMed

51.

Yurci A, Kalkan AO, Ozbakir O, Karaman A, Torun E, Kula M, et al. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. Eur J Gastroenterol Hepatol. 2011;23(12):1206–12. https://doi.org/10.1097/MEG.0b013e32834cd6f6.CrossRefPubMed

52.

Bansal RK, Kumar M, Sachdeva PR, Kumar A. Prospective study of profile of hepatic osteodystrophy in patients with non-choleastatic liver cirrhosis and impact of bisphosphonate supplementation. United European Gastroenterol J. 2016;4(1):77–83. https://doi.org/10.1177/2050640615584535.CrossRefPubMed

Titel: Epidemiology, Diagnosis, and Management of Bone Disease in Patients with Chronic HBV Infection
verfasst von: Mike T. Wei
Mindie H. Nguyen
Ramsey Cheung
Publikationsdatum: 31.07.2019
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 3/2019
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-019-00481-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Economic Analyses to Inform and Support Health Policy for Chronic Hepatitis B Treatment

Management of Virologic Failure in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues

The Role of Liver Biopsy in Drug-Induced Liver Injury

Chronic Hepatitis B in US Veterans

Community-Based Strategies to Improve Screening, Diagnosis and Linkage to Care for Patients with Chronic Hepatitis B